Artia Global Partners LP Vaxcyte, Inc. Transaction History
Artia Global Partners LP
- $498 Billion
- Q1 2024
A detailed history of Artia Global Partners LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Artia Global Partners LP holds 76,255 shares of PCVX stock, worth $5.8 Million. This represents 1.05% of its overall portfolio holdings.
Number of Shares
76,255
Previous 38,555
97.78%
Holding current value
$5.8 Million
Previous $2.42 Billion
115.14%
% of portfolio
1.05%
Previous 0.7%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
269Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$741 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$724 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$584 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$374 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$315 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.51B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...